Provectus Biopharmaceuticals (PVCT)
(Delayed Data from OTC)
$0.10 USD
-0.01 (-7.00%)
Updated Jul 30, 2024 03:30 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Provectus Biopharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 1 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 1 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 3 | 4 | 5 | 5 | 6 |
Income After Depreciation & Amortization | -3 | -3 | -5 | -5 | -6 |
Non-Operating Income | 0 | 0 | 0 | 0 | 1 |
Interest Expense | 0 | 0 | 1 | 2 | 1 |
Pretax Income | -3 | -4 | -6 | -7 | -7 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -3 | -4 | -6 | -7 | -7 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -3 | -4 | -6 | -7 | -7 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -3 | -3 | -5 | -5 | -6 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 1 |
Income After Depreciation & Amortization | -3 | -3 | -5 | -5 | -6 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 419.51 | NA | NA | 393.25 | 386.59 |
Diluted EPS Before Non-Recurring Items | -0.01 | NA | NA | -0.02 | -0.02 |
Diluted Net EPS (GAAP) | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
Fiscal Year end for Provectus Biopharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.24 | 0.12 | 0.07 | 0.16 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.24 | 0.12 | 0.07 | 0.16 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.69 | 0.73 | 0.78 | 0.96 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -0.45 | -0.61 | -0.71 | -0.80 |
Non-Operating Income | NA | 0.00 | 0.00 | 0.00 | 0.02 |
Interest Expense | NA | 0.06 | 0.06 | 0.06 | 0.05 |
Pretax Income | NA | -0.50 | -0.66 | -0.78 | -0.84 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -0.50 | -0.66 | -0.78 | -0.84 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -0.50 | -0.66 | -0.78 | -0.84 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 419.52 | 419.53 | 419.52 | 419.50 |
Diluted EPS Before Non-Recurring Items | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Diluted Net EPS (GAAP) | NA | 0.00 | 0.00 | 0.00 | 0.00 |